| Pharmaceutical Information |
| Drug Name |
Lyxumia |
| Drug ID |
BADD_D01335 |
| Description |
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus (T2DM). It is sold under the brand name Adlyxin by Sanofi-Aventis. Adlyxin recieved FDA approval July 28, 2016 [L763]. |
| Indications and Usage |
For use as an antihyperglycemic agent in the treatment of T2DM [FDA Label]. |
| Marketing Status |
approved |
| ATC Code |
A10BJ03 |
| DrugBank ID |
DB09265
|
| KEGG ID |
D09729
|
| MeSH ID |
C479460
|
| PubChem ID |
90472060
|
| TTD Drug ID |
D05MKA
|
| NDC Product Code |
0024-5745; 0024-5747 |
| UNII |
Not Available
|
| Synonyms |
lixisenatide | DES-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-l-lysyl-l-lysinamide | Adlyxin | AQVE-10010 | ZP10A peptide | ZP 10 | ZP-10 | Lyxumia | AVE 010 | AVE-010 | AVE 0010 | AVE0010 | AVE-0010 |
|
| Chemical Information |
| Molecular Formula |
C215H347N61O65S |
| CAS Registry Number |
320367-13-3 |
| SMILES |
CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN
)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(
C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C
(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(
C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O
)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C
(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(
C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
